Multi-institution evaluation of sequential gemcitabine and docetaxel as rescue therapy for nonmuscle invasive bladder cancer RL Steinberg, LJ Thomas, N Brooks, SL Mott, A Vitale, T Crump, MY Rao, ... The Journal of urology 203 (5), 902-909, 2020 | 132 | 2020 |
100 years of Bacillus Calmette–Guérin immunotherapy: from cattle to COVID-19 N Lobo, NA Brooks, AR Zlotta, JD Cirillo, S Boorjian, PC Black, JJ Meeks, ... Nature Reviews Urology 18 (10), 611-622, 2021 | 106 | 2021 |
Emerging impact of malnutrition on surgical patients: literature review and potential implications for cystectomy in bladder cancer CM Tobert, JM Hamilton-Reeves, LA Norian, C Hung, NA Brooks, ... Journal of Urology 198 (3), 511-518, 2017 | 91 | 2017 |
IRAK4 kinase activity is required for Th17 differentiation and Th17-mediated disease KA Staschke, S Dong, J Saha, J Zhao, NA Brooks, DL Hepburn, J Xia, ... The Journal of Immunology 183 (1), 568-577, 2009 | 86 | 2009 |
Contemporary outcomes of patients with nonmuscle-invasive bladder cancer treated with bacillus Calmette-Guérin: implications for clinical trial design JT Matulay, R Li, PJ Hensley, NA Brooks, VM Narayan, HB Grossman, ... The Journal of urology 205 (6), 1612-1621, 2021 | 38 | 2021 |
Increasing the size of ureteral access sheath during retrograde intrarenal surgery improves surgical efficiency without increasing complications CR Tracy, GM Ghareeb, CJ Paul, NA Brooks World journal of urology 36, 971-978, 2018 | 38 | 2018 |
Increasing the size of ureteral access sheath during retrograde intrarenal surgery improves surgical efficiency without increasing complications CR Tracy, GM Ghareeb, CJ Paul, NA Brooks World journal of urology 36, 971-978, 2018 | 38 | 2018 |
The association of Coronavirus Disease-19 mortality and prior bacille Calmette-Guerin vaccination: a robust ecological analysis using unsupervised machine learning NA Brooks, A Puri, S Garg, S Nag, J Corbo, AE Turabi, N Kaka, ... Scientific reports 11 (1), 774, 2021 | 34 | 2021 |
Critical analysis of quality of life and cost-effectiveness of enhanced recovery after surgery (ERAS) for patient’s undergoing urologic oncology surgery: a systematic review NA Brooks, A Kokorovic, JS McGrath, W Kassouf, JW Collins, PC Black, ... World journal of urology, 1-18, 2020 | 31 | 2020 |
Treatment options in non-muscle-invasive bladder cancer after BCG failure NA Brooks, MA O’Donnell Indian journal of urology 31 (4), 312-319, 2015 | 26 | 2015 |
Pilot study to determine optimal stent duration following ureteroscopy: three versus seven days CJ Paul, NA Brooks, GM Ghareeb, CR Tracy Current urology 11 (2), 97-102, 2018 | 23 | 2018 |
Current therapy and emerging intravesical agents to treat non–muscle invasive bladder cancer KK Bree, NA Brooks, AM Kamat Hematology/Oncology Clinics 35 (3), 513-529, 2021 | 19 | 2021 |
Bladder neck contracture following radical retropubic versus robotic-assisted laparoscopic prostatectomy BL Spector, NA Brooks, ME Strigenz, JA Brown Current urology 10 (3), 145-149, 2017 | 19 | 2017 |
Patterns of metastases of prostatic ductal adenocarcinoma WKB Ranasinghe, NA Brooks, MA Elsheshtawi, JW Davis, TK Bathala, ... Cancer 126 (16), 3667-3673, 2020 | 17 | 2020 |
Bacillus Calmette-Guerin strain may not effect recurrence-free survival when used intravesically with interferon-alpha2b for non–muscle-invasive bladder cancer RL Steinberg, NA Brooks, LJ Thomas, SL Mott, MA O’Donnell Urologic Oncology: Seminars and Original Investigations 35 (5), 201-207, 2017 | 17 | 2017 |
Pushing stones uphill: why patients are lost to follow-up after uncomplicated ureteroscopy NA Brooks, CJ Paul, GM Ghareeb, CR Tracy Journal of endourology 31 (2), 135-140, 2017 | 16 | 2017 |
Intravesical sequential gemcitabine and docetaxel versus bacillus calmette-guerin (BCG) plus interferon in patients with recurrent non-muscle invasive bladder cancer following … RL Steinberg, VT Packiam, LJ Thomas, N Brooks, A Vitale, SL Mott, ... Urologic Oncology: Seminars and Original Investigations 40 (1), 9. e1-9. e7, 2022 | 14 | 2022 |
The obesity paradox: defining the impact of body mass index and diabetes mellitus for patients with non‐muscle‐invasive bladder cancer treated with bacillus Calmette–Guérin NA Brooks, A Kokorovic, L Xiao, JT Matulay, R Li, WKB Ranasinghe, ... BJU international 128 (1), 65-71, 2021 | 12 | 2021 |
All high-grade Ta tumors should be classified as high risk: bacillus Calmette-Guérin response in high-grade Ta tumors KK Bree, PJ Hensley, N Lobo, NA Brooks, GM Nogueras-Gonzalez, ... Journal of Urology 208 (2), 284-291, 2022 | 11 | 2022 |
Nongenitourinary complications associated with robot-assisted laparoscopic and radical retropubic prostatectomy: a single institution assessment of 1,100 patients over 11 years NA Brooks, RS Boland, ME Strigenz, SL Mott, JA Brown Urologic Oncology: Seminars and Original Investigations 36 (11), 501. e9-501 …, 2018 | 10 | 2018 |